Product rights agreement, quarterly payments, expiration date

No definition available.

Name:	cpix_ProductRightsAgreementQuarterlyPaymentsExpirationDate
Namespace Prefix:	cpix_
Data Type:	us-types:durationStringItemType
Balance Type:	na
Period Type:	duration

- Definition

Product Rights Agreement, Quarterly Payments Made

+ References

No definition available.

+ Details

Name:	cpix_ProductRightsAgreementQuarterlyPaymentsMade
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue Recognition, Potential Upfront Payment Related to Product Sales

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=cpix_PernixTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=cpix_VaprisolMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cpix_KristaloseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_ProductRightsAgreementUSCommercializationRightsForKristaloseFromInalcoBiochemicalsIncAndInalcoSPAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Intangible Assets (Narrative) (Details) (USD $)	12 Months Ended			0 Months Ended
Intangible Assets (Narrative) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 29, 2013	Feb. 28, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 1,596,689us-gaap_AmortizationOfIntangibleAssets	$ 896,156us-gaap_AmortizationOfIntangibleAssets	$ 506,332us-gaap_AmortizationOfIntangibleAssets
Additions to intangible assets	3,101,565	7,462,080	2,071,926
Product and License Rights
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	16,477,749	12,139,031
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	8,194,264	4,866,570
Additions to intangible assets	3,300,000	2,100,000
Product, Kristalose \| Product and License Rights
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	15 years
Collaborative Arrangement, Amended International Agreement
Acquired Finite-Lived Intangible Assets [Line Items]
Other revenue, potential upfront payment related to product sales		4,000,000
Product Rights Agreement, U.S. Commercialization Rights for Kristalose from Inalco Biochemicals, Inc. and Inalco S.p.A. \| Product, Kristalose \| Product and License Rights
Acquired Finite-Lived Intangible Assets [Line Items]
Product rights agreement, quarterly payments, expiration date	7 years
Quarterly payments made	1,300,000	800,000
Product, Vaprisol \| Product and License Rights
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross					3,000,000
Pernix Therapeutics \| Collaborative Arrangement, Amended International Agreement
Acquired Finite-Lived Intangible Assets [Line Items]
Other revenue, potential upfront payment related to product sales	$ 3,000,000			$ 4,000,000